This is a routine, prearranged sale by a non-executive director and does not signal material concern. Traders should monitor for completion of these sales in upcoming Form 4 filings, but no immediate price impact is expected.
CGON drugs
CGON drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 20 $70.40entry
- T+1 · 7mo ago +2.05%α +2.70% · $71.84
- T+5 · 7mo ago −5.09%α −6.00% · $66.82
- T+20 · 6mo ago −10.61%α −14.81% · $62.93
- T+60 · 4mo ago +3.69%α −3.08% · $73.00
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
James Mule, a director at CG Oncology, filed a Form 144 to notify intent to sell up to 17,564 shares of common stock, received through the exercise of stock options. The filing indicates planned sales under a 10b5-1 plan, with option exercises occurring as early as March 2026.
Key Facts
- James Mule, director of CG Oncology, intends to sell 17,564 shares of common stock
- Shares were or will be acquired through exercise of stock options between March 2026 and June 2025
- Sales are being conducted under a 10b5-1 plan, indicating prearranged trading strategy
- Total value of shares to be sold is approximately $116,514 based on current market price
- Filing date is April 17, 2026, with option exercises already initiated as of March 16, 2026
Financial Impact
Approximately $116,514 in shares to be sold, representing a small fraction of the company's $5.6B market cap
Risk Factors
- Potential perception of insider selling if market conditions deteriorate
- Downward pressure on stock price if sale is executed rapidly near-term
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-003597 |
| Document: 0001950047-26-003597-index.html | 0001950047-26-003597 |
| Document: 0001950047-26-003597.txt | 0001950047-26-003597 |
Track record
25 reports on CGON
6 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +26.33% at T+20 after the Jun 12, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 16, 2026today 8-K Bullish 7/10 Entry $98.84 Now $84.78 −14.23% settles Dec 15
- Nov 16, 2026today Press Release Bullish 7/10 Entry $95.01 Now $84.78 −10.77% settles Dec 15
- Nov 6, 202610d ago 8-K Bearish 5/10 Entry $75.99 Now $84.78 −11.57% settles Dec 7
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $75.99 Now $84.78 +11.57% settles Dec 7
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $64.06 Now $84.78 +32.34% settles Dec 2
- Oct 19, 202628d ago 3 Neutral 2/10 Entry $61.93 Now $84.78 +36.90% settles Nov 17
- Oct 15, 20264w ago 144 Neutral 2/10 Entry $59.85 to $74.40 Now $84.78 +41.65% ▲ +24.31% +25.47% vs SPY
- Oct 12, 20265w ago Institutional Cluster Mixed 3/10 Entry $63.13 to $74.74 Now $84.78 +34.29% ▲ +18.39% +21.66% vs SPY
- Aug 6, 202614w ago Press Release Bearish 7/10 Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
- Aug 6, 202614w ago 424B5 Bearish 6/10 Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers